Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
Gavila J, Seguí MÁ, Calvo L, López T, Alonso JJ, Farto M, Sánchez-de la Rosa R
Clin Transl Oncol. 2017 Jan;19(1):91-104
CARDIONCOLOGY.ORG ABSTRACT:
This report is the first to produce a set of statements on the prevention, evaluation and monitoring of chemotherapy-induced cardiac toxicity in breast cancer patients.bBreast cancer is generally treated with anthracyclines (80 %).
A decline of left ventricular ejection fraction (LVEF) >10 %, to an LVEF value <53 % was suggested as a criterion for changing the dose schedule of anthracyclines, or suspending the treatment of chemotherapy plus trastuzumab until the normalization of the left ventricular function.
The use of liposomal anthracyclines was strongly suggested as a treatment option for breast cancer patients.
© All Rights Reserved